Celcuity

CELC · NASDAQ

$60.00+$2.88 (+5.04%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $57.12

Latest news

Press releaseOct 2, 8:00 AM ETGlobe Newswire
Celcuity Appoints David Gryska To Its Board Of Directors
Press releaseSep 30, 8:00 AM ETGlobe Newswire
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
NewsSep 11, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
Press releaseAug 26, 8:30 AM ETGlobe Newswire
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
NewsAug 14, 8:29 AM ETAvi Kapoor
Celcuity Analysts Slash Their Forecasts After Q2 Loss
NewsAug 13, 5:24 PM ET
Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseAug 13, 4:06 PM ETGlobe Newswire
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseAug 6, 11:02 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Press releaseAug 4, 5:45 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Press releaseAug 4, 5:43 PM ETGlobe Newswire
Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
Press releaseAug 3, 8:19 PM ETBusiness Wire
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Press releaseAug 2, 5:27 PM ETBusiness Wire
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
Press releaseJul 31, 11:22 AM ETPRNewswire
CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Press releaseJul 30, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC
Press releaseJul 30, 8:30 AM ETGlobe Newswire
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Press releaseJul 29, 10:55 AM ETGlobe Newswire
NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Press releaseJul 28, 7:50 PM ETBusiness Wire
NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Press releaseJul 28, 5:31 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Press releaseJul 21, 4:58 PM ETGlobe Newswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
Press releaseJul 21, 1:26 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Press releaseJul 20, 8:00 PM ETGlobe Newswire
CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Press releaseJul 16, 7:52 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
NewsJul 15, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseJul 14, 4:53 PM ETGlobe Newswire
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
Press releaseJun 3, 10:13 PM ETGlobe Newswire
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Press releaseJun 3, 7:19 AM ETGlobe Newswire
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
NewsJun 2, 1:37 PM ETVandana Singh
What's Going On With Celcuity Stock On Tuesday?
NewsMay 15, 1:13 PM ETVandana Singh
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst
NewsMay 14, 5:21 PM ET
Transcript: Celcuity Q1 2026 Earnings Conference Call
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
NewsMay 4, 9:54 AM ETAvi Kapoor
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
NewsMay 4, 7:05 AM ETVandana Singh
Why Is Celcuity Stock Rallying Today?
NewsMar 25, 7:11 AM ET
Earnings Scheduled For March 25, 2026
Press releaseJan 8, 12:08 PM ETGlobe Newswire
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
NewsDec 12, 12:08 PM ETAvi Kapoor
RH Posts Strong Q3 Sales, Joins Canopy Growth, Tilray Brands, Frequency Electronics And Other Big Stocks Moving Higher On Friday
NewsNov 12, 6:11 AM ET
Earnings Scheduled For November 12, 2025
NewsNov 11, 9:03 AM ET
Exploring Celcuity's Earnings Expectations
NewsOct 20, 9:49 AM ETAvi Kapoor
Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results
Press releaseOct 7, 9:00 AM ETPRNewswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
Press releaseOct 7, 9:00 AM ETPRNewswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
Press releaseOct 7, 9:00 AM ETPRNewswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
NewsAug 13, 10:02 AM ET
Insights into Celcuity's Upcoming Earnings
Press releaseJul 29, 3:46 PM ETPRNewswire
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
NewsJul 28, 12:05 PM ETAvi Kapoor
Crude Oil Gains 2%; CEA Industries Shares Spike Higher
NewsJul 28, 10:03 AM ETAvi Kapoor
US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings
NewsJul 28, 9:42 AM ETVandana Singh
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Celcuity Appoints David Gryska To Its Board Of Directors

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

10 Health Care Stocks With Whale Alerts In Today’s Session

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm

CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law

CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

12 Health Care Stocks Moving In Wednesday's Intraday Session

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

What's Going On With Celcuity Stock On Tuesday?

Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst

Transcript: Celcuity Q1 2026 Earnings Conference Call

Earnings Scheduled For May 14, 2026

Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday

Why Is Celcuity Stock Rallying Today?

Earnings Scheduled For March 25, 2026

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

RH Posts Strong Q3 Sales, Joins Canopy Growth, Tilray Brands, Frequency Electronics And Other Big Stocks Moving Higher On Friday

Earnings Scheduled For November 12, 2025

Exploring Celcuity's Earnings Expectations

Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

Insights into Celcuity's Upcoming Earnings

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Crude Oil Gains 2%; CEA Industries Shares Spike Higher

US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings

Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer